Wednesday, July 8, 2026

pharma · Non-muscle invasive bladder cancer (NMIBC) · Low Grade Upper Tract Urothelial Carcinoma · TYRA

Tyra Biosciences

Tyra Biosciences is a pharma organization headquartered in Carlsbad, USA. It trades on NYSE under ticker TYRA. Primary therapeutic focus areas include Non-muscle invasive bladder cancer (NMIBC), Low Grade Upper Tract Uro

Carlsbad, USA HQ
93 Employees
Public company Type
TYRA · NYSE Ticker
Company details
Status
Public
HQ
Carlsbad, USA
Employees
93
Programs
9
Drugs
3
Patents
17
Clinical program

TYRA-300-B01

Phase 1 · small molecule · Healthy

TYRA-300-B01 for Healthy is a Phase 1 program (small_molecule) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).

← All Tyra Biosciences projects Phase 1 small molecule active

Internal code TYR300-102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tyra Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
active
Trials
1

Clinical trials